2. Search Result
Search Result
Results for "

Cannabinoid 1 receptor

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15443
    AM251
    Maximum Cited Publications
    23 Publications Verification

    		 Cannabinoid Receptor Neurological Disease
    AM251 is a selective cannabinoid 1 (CB1) receptor antagonist with an IC50 of 8 nM. AM251 also acts as a potent GPR55 agonist with an EC50 of 39 nM .
    AM251
  • HY-100197
    Synaptamide
    1 Publications Verification

    N-Docosahexaenoyl ethanolamine (DHEA); Docosahexaenoyl ethanolamide

    		 Cannabinoid Receptor Neurological Disease
    Synaptamide (Dehydroepiandrosteron; DHEA) is an endogenous metabolite and structural analogue of Anandamide. Synaptamide binds to both the cannabinoid-1 and 2 (CB1 and CB2) cannabinoid receptors and has anti-inflammatory properties. Synaptamide is the first small-molecule endogenous ligand of an adhesion G protein-coupled receptor (aGPCR) .
    Synaptamide
  • HY-10013
    Taranabant
    2 Publications Verification

    MK-0364

    		 Cannabinoid Receptor Metabolic Disease
    Taranabant is a highly potent and selective cannabinoid 1 (CB1) receptor inverse agonist that inhibits the binding and functional activity of various agonists, with a binding Ki of 0.13 nM for the human CB1R in vitro.
    Taranabant
  • HY-14791A
    (±)-Ibipinabant
    1 Publications Verification

    (±)-SLV319; (±)-BMS-646256

    		 Cannabinoid Receptor Metabolic Disease
    (±)-Ibipinabant ((±)-SLV319) is the racemate of SLV319. (±)-Ibipinabant ((±)-SLV319) is a potent and selective cannabinoid-1 (CB-1) receptor antagonist with an IC50 of 22 nM.
    (±)-Ibipinabant
  • HY-10013A
    Taranabant racemate

    MK-0364 racemate

    		 Cannabinoid Receptor Neurological Disease
    Taranabant racemate (MK-0364 racemate) is an antagonist and/or inverse agonist of the Cannabinoid-1 (CB1) receptor extracted from patent WO 2004048317 A1 .
    Taranabant racemate
  • HY-118140
    ZCZ011

    		Cannabinoid Receptor Neurological Disease Inflammation/Immunology
    ZCZ011 is a potent and brain-penetrant cannabinoid 1 (CB1) receptor positive allosteric modulator. ZCZ011 potentiates binding of CP55,940 to the CB1 receptor, enhances anandamide (AEA)-stimulated GTPγS binding in mouse brain membranes. ZCZ011 increases β-arrestin recruitment and ERK phosphorylation in hCB1 cells. ZCZ011 can be used for researching neuropathic and inflammatory pain .
    ZCZ011
  • HY-150067
    CB1R antagonist 1

    		Cannabinoid Receptor Metabolic Disease
    CB1R Allosteric modulator 5, a selective cannabinoid-1 receptor (CB1R) inverse agonist with an IC50 value of 4.2 μM and EC50 value of ＞10 μM. CB1R Allosteric modulator 5 can be used for the research of metabolic and obesity .
    CB1R antagonist 1
  • HY-168997
    CB1R agonist 1

    		Cannabinoid Receptor Neurological Disease Inflammation/Immunology
    CB1R agonist 1 is a potent, CNS-penetrant, and selective Cannabinoid-1 receptor (CB1R) agonist with a Ki of 0.95 nM, modulating Gi/o signaling. CB1R agonist 1 exhibits high selectivity over CB2R and other off-target GPCRs, including GPR55, GPR18, and GPR119. CB1R agonist 1 induces analgesia and hypothermia, and potentiates opioid analgesia in mice. CB1R agonist 1 can be used for the research of pain .
    CB1R agonist 1
  • HY-103330
    TC-C 14G

    		Cannabinoid Receptor Neurological Disease
    TC-C 14G (Compd 14g) is a Cannabinoid-1 Receptor (CB1R) inverse agonist, with a Ki of 4 nM and EC50 of 11 nM for HCB1R, respectively .
    TC-C 14G
  • HY-12104
    PF-514273

    		Cannabinoid Receptor Metabolic Disease
    PF-514273 is an orally active, selective antagonist for cannabinoid-1 receptor (CB1) with IC50 of 1 nM. PF-514273 reduces the food uptake in mice, and can be used for obesity research .
    PF-514273
  • HY-113689
    GAT211

    		Cannabinoid Receptor Neurological Disease
    GAT211 is a cannabinoid 1 receptor (CB1R) positive allosteric modulator (PAM). GAT211 activates cAMP and β-arrestin2 with EC50 values of 260 nM and 650 nM, respectively. GAT211 inhibits GAT211 can be used for neuropathic and/or inflammatory pain research .
    GAT211
  • HY-172808
    BNS808

    		Cannabinoid Receptor Cytochrome P450 Metabolic Disease
    BNS808 is an orally active and selective cannabinoid-1 receptor (CB1R) antagonist (IC50 = 0.8 nM) with notable CB2R selectivity and minimal brain penetration. BNS808 is studied in research on obesity and its associated metabolic complications, such as metabolic dysfunctional-associated steatotic liver disease (MASLD). BNS808 has reduced free drug availability for CNS entry, enhancing safety and minimizing drug-drug interactions through high plasma binding .
    BNS808
  • HY-10013B
    Taranabant ((1R,2R)stereoisomer)

    MK0364 (1R,2R)stereoisomer

    		 Cannabinoid Receptor Others
    Taranabant (1R,2R)stereoisomer is the R-enantiomer of Taranabant. Taranabant is a highly potent and selective cannabinoid 1 (CB1) receptor inverse agonist.
    Taranabant ((1R,2R)stereoisomer)
  • HY-183113
    CB1-receptor agonist-1

    		Cannabinoid Receptor Neurological Disease
    CB1-receptor agonist-1 is the racemic form of compound ‘1350 and is also a cannabinoid-1 receptor (CB1R) agonist .
    CB1-receptor agonist-1
  • HY-15443R
    AM251 (Standard)

    		Cannabinoid Receptor Neurological Disease
    AM251 (Standard) is the analytical standard of AM251. This product is intended for research and analytical applications. AM251 is a selective cannabinoid 1 (CB1) receptor antagonist with an IC50 of 8 nM. AM251 also acts as a potent GPR55 agonist with an EC50 of 39 nM .
    AM251 (Standard)
  • HY-14791AR
    (±)-Ibipinabant (Standard)

    (±)-SLV319 (Standard); (±)-BMS-646256 (Standard)

    		 Cannabinoid Receptor Reference Standards Metabolic Disease
    (±)-Ibipinabant (Standard) is the analytical standard of (±)-Ibipinabant. This product is intended for research and analytical applications. (±)-Ibipinabant ((±)-SLV319) is the racemate of SLV319. (±)-Ibipinabant ((±)-SLV319) is a potent and selective cannabinoid-1 (CB-1) receptor antagonist with an IC50 of 22 nM.
    (±)-Ibipinabant (Standard)
  • HY-144705
    GAT564

    		Cannabinoid Receptor Neurological Disease
    GAT564 (Compound 15d) is a potent allosteric modulator of cannabinoid 1 receptor (CB1R) with EC50s of 87 and 320 nM respectively for cAMP and β-arrestin2. GAT564 markedly promotes orthosteric ligand binding to hCB1R. GAT564 is efficacious as a topical agent that significantly reduces intraocular pressure (IOP) in the ocular normotensive murine model of glaucoma .
    GAT564
  • HY-10013BR
    Taranabant ((1R,2R)stereoisomer) (Standard)

    MK0364 (1R,2R)stereoisomer (Standard)

    		 Cannabinoid Receptor Reference Standards Others
    Taranabant ((1R,2R)stereoisomer) (Standard) is the analytical standard of Taranabant ((1R,2R)stereoisomer) (HY-10013B). This product is intended for research and analytical applications. Taranabant (1R,2R)stereoisomer is the R-enantiomer of Taranabant. Taranabant is a highly potent and selective cannabinoid 1 (CB1) receptor inverse agonist.
    Taranabant ((1R,2R)stereoisomer) (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: